Ultra-fast, multiplex molecular POCT

PCR|ONE offers unique combination of 15-minute TAT speed with 20-target multiplexing capacity.

BacterOmic delivers complete information on phenotypic antibiotic susceptibility of bacterial pathogens: MIC values for all antibiotics and synergies between up to 20 combinations. It enables precision therapies already after the first test.

Patented infrared and microfluidic solutions to offer unique combination of speed, breath of test menu and adaptability of the DNA/RNA test panels.

  • Infection prevention
  • Microbial diagnostics
  • Antimicrobial stewardship
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Viruses
  • Yeasts
  • Fungi
  • Parasites

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Development
  • Research
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • Co-develop
  • Joint Venture
  • Sell
  • License
  • Outsource

Funding organisation:

    Infectious disease area:

      Geographic origin:

        We seek strategic partnership with a global diagnostic systems supplier that can best leverage the market value of Bacteromic, offering complete AST information for targeted antibiotics therapies, within established workflow and test-price structure.

        Founded in 2012, Curiosity Dx, a med-tech startup with a team of 40 people developed PCR|ONE: ultrafast & comprehensive POCT molecular Dx system.

        PCR|ONE is part of Scope Fluidics Group which in parallel develops BacterOMIC system designed to offer actionable AST information – MIC values for all clinically relevant antibiotics or up to 20 antibiotic combinations from a single assay.

        What is going on with AMR?
        Stay tuned with remarkable global AMR news and developments!